IN2012DN00869A - - Google Patents

Download PDF

Info

Publication number
IN2012DN00869A
IN2012DN00869A IN869DEN2012A IN2012DN00869A IN 2012DN00869 A IN2012DN00869 A IN 2012DN00869A IN 869DEN2012 A IN869DEN2012 A IN 869DEN2012A IN 2012DN00869 A IN2012DN00869 A IN 2012DN00869A
Authority
IN
India
Prior art keywords
formula
compounds
raf
useful
treatment
Prior art date
Application number
Inventor
Abran Q Constales
Shenlin Huang
Jeff Xianming Jin
Zuosheng Liu
Sabina Pecchi
Daniel Poon
John TELLEW
Qiong Zhang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IN2012DN00869A publication Critical patent/IN2012DN00869A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The present invention provides compounds of Formula (I) or (II) wherein R1, R1b, R2, R3, R4, R5, R6 and R7 are defined herein. The compounds of Formula (I) or (II) and pharmaceutical compositions thereof are useful for the treatment of B-Raf-associated diseases.
IN869DEN2012 2009-08-28 2010-08-26 IN2012DN00869A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23808309P 2009-08-28 2009-08-28
US31306110P 2010-03-11 2010-03-11
PCT/EP2010/062495 WO2011023773A1 (en) 2009-08-28 2010-08-26 Compounds and compositions as protein kinase inhibitors

Publications (1)

Publication Number Publication Date
IN2012DN00869A true IN2012DN00869A (en) 2015-07-10

Family

ID=42829939

Family Applications (1)

Application Number Title Priority Date Filing Date
IN869DEN2012 IN2012DN00869A (en) 2009-08-28 2010-08-26

Country Status (19)

Country Link
US (3) US8242260B2 (en)
EP (1) EP2470528B1 (en)
JP (1) JP5726190B2 (en)
KR (1) KR101714107B1 (en)
CN (1) CN102596937B (en)
AR (1) AR077977A1 (en)
AU (1) AU2010288455B2 (en)
BR (1) BR112012004448A2 (en)
CA (1) CA2771673C (en)
EA (1) EA020479B1 (en)
ES (1) ES2527176T3 (en)
IN (1) IN2012DN00869A (en)
JO (1) JO3007B1 (en)
MX (1) MX2012002542A (en)
PL (1) PL2470528T3 (en)
PT (1) PT2470528E (en)
TW (1) TWI487701B (en)
UY (1) UY32859A (en)
WO (1) WO2011023773A1 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3002B1 (en) 2009-08-28 2016-09-05 Irm Llc Compounds and compositions as protein kinase inhibitors
EP3028699B1 (en) 2010-02-25 2018-03-21 Dana-Farber Cancer Institute, Inc. Braf mutations conferring resistance to braf inhibitors
US9498471B2 (en) 2011-10-20 2016-11-22 The Regents Of The University Of California Use of CDK9 inhibitors to reduce cartilage degradation
CN108542906A (en) 2011-11-11 2018-09-18 诺华股份有限公司 The method for treating proliferative disease
PT2782557T (en) 2011-11-23 2018-11-26 Array Biopharma Inc Pharmaceutical formulations
US9408885B2 (en) 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
WO2014047330A1 (en) * 2012-09-19 2014-03-27 Jean-Michel Vernier Novel raf kinase inhibitors
US9242969B2 (en) * 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
AU2014274093B2 (en) 2013-05-30 2018-11-08 Plexxikon Inc. Compounds for kinase modulation, and indications therefor
BR112015031432A2 (en) 2013-06-25 2017-07-25 Bristol Myers Squibb Co carbazole carboxamide compounds useful as kinase inhibitors
TWI648272B (en) 2013-06-25 2019-01-21 美商必治妥美雅史谷比公司 Substituted tetrahydrocarbazole and carbazole carbamide compounds
UA116675C2 (en) * 2013-08-28 2018-04-25 Медівейшн Текнолоджіс Ллк Heterocyclic compounds and methods of use
GB2517988A (en) * 2013-09-09 2015-03-11 Redx Pharma Ltd Compounds
UY36294A (en) 2014-09-12 2016-04-29 Novartis Ag COMPOUNDS AND COMPOSITIONS AS QUINASA INHIBITORS
WO2016061144A1 (en) 2014-10-14 2016-04-21 The Regents Of The University Of California Use of cdk9 and brd4 inhibitors to inhibit inflammation
CN104402920B (en) * 2014-11-27 2018-04-03 河南科技学院 A kind of method for synthesizing the chloroaniline of 2 halo, 3 pinacol borate 5
WO2018146253A1 (en) 2017-02-10 2018-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the mapk pathway
JP7416716B2 (en) 2017-12-28 2024-01-17 トラクト ファーマシューティカルズ インコーポレイテッド Stem cell culture system for columnar epithelial stem cells and related uses
WO2020124397A1 (en) * 2018-12-19 2020-06-25 Inventisbio Shanghai Ltd. C-terminal src kinase inhibitors
EP4196228A1 (en) * 2020-08-13 2023-06-21 Albert Einstein College of Medicine N-cyclyl-sulfonamides useful for inhibiting raf
WO2023240024A1 (en) 2022-06-08 2023-12-14 Nikang Therapeutics, Inc. Sulfamide derivatives as cyclin-dependent kinase 2 inhibitors

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2659739A (en) 1950-04-14 1953-11-17 Eastman Kodak Co 1-hydroxy-4-beta-cyanopropylamino-anthraquinone and process for preparing same
US6358932B1 (en) 1994-05-31 2002-03-19 Isis Pharmaceticals, Inc. Antisense oligonucleotide inhibition of raf gene expression
US6391636B1 (en) 1994-05-31 2002-05-21 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US6037136A (en) 1994-10-24 2000-03-14 Cold Spring Harbor Laboratory Interactions between RaF proto-oncogenes and CDC25 phosphatases, and uses related thereto
US5717100A (en) 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
GB2306108A (en) * 1995-10-13 1997-04-30 Merck & Co Inc Treatment of Raf-mediated cancers with imidazole derivatives
IL127210A0 (en) 1996-05-23 1999-09-22 Applied Research Systems Compounds inhibiting the binding of raf-1 or 13-3-3 proteins to the beta-chain of il-2 pharmaceutical compositions containing them and their use
AR012634A1 (en) 1997-05-02 2000-11-08 Sugen Inc QUINAZOLINE BASED COMPOUND, FAMACEUTICAL COMPOSITION THAT UNDERSTANDS IT, METHOD TO SYNTHESIZE IT, ITS USE, METHODS OF MODULATION OF THE DESERINE / TREONIN PROTEIN-KINASE FUNCTION AND IN VITRO METHOD TO IDENTIFY COMPOUNDS THAT MODULATE
US6187799B1 (en) 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
US6204467B1 (en) 1998-03-24 2001-03-20 Ford Global Technologies, Inc. Method and apparatus for resistive welding
RU2319693C9 (en) 1999-01-13 2008-08-20 Байер Копэрейшн Derivatives of urea (variants), pharmaceutical composition (variants) and method for treatment of diseases associated with cancer cells growth (variants)
WO2002018654A1 (en) 2000-08-30 2002-03-07 The Board Of Trustees Of The University Of Arkansas Induction of ldl receptor expression by extracellular-signal regulated kinase, erk-1/2
SI1482932T1 (en) 2002-03-13 2010-02-26 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
US6644516B1 (en) 2002-11-06 2003-11-11 Continental Afa Dispensing Company Foaming liquid dispenser
JP2008531537A (en) 2005-02-25 2008-08-14 クドス ファーマシューティカルズ リミテッド Compound
KR20070113252A (en) 2005-02-25 2007-11-28 쿠도스 파마슈티칼스 리미티드 2,4-diamino-pyridopyrimidine derivatives and their use as mtor inhibitors
KR101464384B1 (en) 2005-11-22 2014-11-21 쿠도스 파마슈티칼스 리미티드 PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
JP2009523161A (en) 2006-01-11 2009-06-18 アストラゼネカ アクチボラグ Morpholinopyrimidine derivatives and their use in therapy
MX2009001946A (en) 2006-08-23 2009-03-05 Kudos Pharm Ltd 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors.
TW200922582A (en) 2007-08-20 2009-06-01 Organon Nv N-benzyl, N'-arylcarbonylpiperazine derivatives
BRPI0908906A2 (en) * 2008-03-21 2019-09-24 Novartis Ag heterocyclic compounds and their uses
UA103319C2 (en) * 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
US8541575B2 (en) * 2008-07-24 2013-09-24 Nerviano Medical Sciences S.R.L. 3,4-diarylpyrazoles as protein kinase inhibitors

Also Published As

Publication number Publication date
CN102596937B (en) 2014-02-12
AR077977A1 (en) 2011-10-05
AU2010288455B2 (en) 2013-01-31
US8859548B2 (en) 2014-10-14
US20140011825A1 (en) 2014-01-09
US8242260B2 (en) 2012-08-14
KR101714107B1 (en) 2017-03-08
EA020479B1 (en) 2014-11-28
EA201200323A1 (en) 2012-09-28
EP2470528B1 (en) 2014-10-01
ES2527176T3 (en) 2015-01-21
WO2011023773A1 (en) 2011-03-03
BR112012004448A2 (en) 2017-05-30
CA2771673C (en) 2016-07-12
TWI487701B (en) 2015-06-11
CN102596937A (en) 2012-07-18
MX2012002542A (en) 2012-04-02
PL2470528T3 (en) 2015-03-31
CA2771673A1 (en) 2011-03-03
KR20120092577A (en) 2012-08-21
UY32859A (en) 2011-03-31
PT2470528E (en) 2014-12-29
AU2010288455A1 (en) 2012-02-23
JO3007B1 (en) 2016-09-05
JP5726190B2 (en) 2015-05-27
EP2470528A1 (en) 2012-07-04
TW201111365A (en) 2011-04-01
US20110052578A1 (en) 2011-03-03
US8563553B2 (en) 2013-10-22
JP2013503139A (en) 2013-01-31
US20120225899A1 (en) 2012-09-06

Similar Documents

Publication Publication Date Title
IN2012DN00869A (en)
GEP20135964B (en) Inhibitors of beta-secretase
MY153915A (en) Organic compounds
MX2010009752A (en) Oxadiazoanthracene compounds for the treatment of diabetes.
UA102251C2 (en) Aminidihydrothiazine derivatives as bace inhibitors for the treatment of alzheimer's disease
SI2134691T1 (en) Quinolinone derivatives as parp and tank inhibitors
MX2014012695A (en) Isoindolone derivatives.
MY160468A (en) Novel amino azaheterocyclic carboxamides
MX353257B (en) Heterocyclic compounds useful as pdk1 inhibitors.
TW200716606A (en) Chemical compounds
DK1853602T3 (en) Chemical compounds
TW200800963A (en) Chemical compounds
DK1853588T3 (en) Chemical compounds
GEP20146125B (en) Aminopyrimidines as syk inhibitors
MX2014002770A (en) New dihydroquinoline-2-one derivatives.
SG178952A1 (en) Chemical compounds
IN2012DN01233A (en)
IN2012DN00971A (en)
MX2012003644A (en) 2-pyridone compounds used as inhibitors of neutrophil elastase.
EA201170832A1 (en) PURINE CONNECTIONS
MX2012001413A (en) Novel azaheterocyclic compounds.
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
MX2013002851A (en) Inhibitors of notum pectinacetylesterase and methods of their use.
GEP20135959B (en) Aryl piperazine and their usage as alpha2c antagonists
EA201170344A1 (en) AZAINDOL IAP INHIBITORS